GCL
BPMC

Glazer Capital LLC’s Blueprint Medicines BPMC Stock Holding History

Glazer Capital LLC’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,331,300
Closed -$171M – 311
2025
Q2 		$171M Buy
+1,331,300
New +$138M 6.1% 3

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Glazer Capital LLC's BPMC Position: Q3 2025 in Review

Glazer Capital LLC sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,331,300 shares — an estimated $171M sold.

Glazer Capital LLC first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $171M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Glazer Capital LLC reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Glazer Capital LLC sold 1,331,300 Blueprint Medicines shares in Q3 2025, an estimated $171M.
  • Glazer Capital LLC first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
  • Glazer Capital LLC's Blueprint Medicines position peaked at $171M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Glazer Capital LLC's 13F filing for Q3 2025, filed 13 Nov 2025.